RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancer
On October 16, 2023 the ESMO metastatic pancreatic cancer abstract was released preliminary updated PDAC data showing a 6-month surivial rate of 82% in a patient population comprised of patients where 92% presented with metastatic disease, 69% in the liver - the worst of the worst - which historically only 10% survive longer than one (1) year.
The results showed that 8 of 13 evaluable patients had a partial response (PR) in a patient population which historically have not responded to in the past. A partial response (PR) is defined as at least a 30% decrease in the sum of the target lesions.
This is the first time that any study demonstrated that a checkpoint inhibitor in an I/O combination can be effective in the treatment of pancreatic cancer.
By example, a recently published phase I study of nivolumab and the anti-CC chemokine receptor 4 antibody mogamulizumab in patients with advanced solid tumors included 15 patients with PDAC. The authors reported 1 confirmed partial response and 2 unconfirmed partial responses in patients with PDAC.
Besides data from the study showing that 8 of 13 evaluable patients had a partial response (PR) and 3 had stable disease (SD) for an objective response rate (ORR) of 62% (53% confirmed with two scans) and a clinical benefit rate (CBR) of 85%. As of the data cut-off (January 19, 2023), the median duration of response was 6.0 months, the 6-month progression-free survival (PFS) rate was 72.9%, and the 6-month overall survival (OS) rate was 82.1%. T cell receptor sequencing (TCR-seq) showed an expansion of new and pre-existing T-cell clones. No safety signals were observed.
https://www.newswire.ca/news-releases/oncolytics-biotech-r-to-present-two-posters-on-the-pelareorep-based-goblet-study-at-esmo-2023-839114142.html